Global Antisense & RNAi Therapeutics Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Antisense & RNAi Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Antisense & RNAi Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 RNA interference
  • 1.4.3 SiRNA
  • 1.4.4 MiRNA
  • 1.4.5 Antisense RNA
• 1.5 Market by Application
  • 1.5.1 Global Antisense & RNAi Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Oncology
  • 1.5.3 Cardiovascular
  • 1.5.4 Renal
  • 1.5.5 Neurodegenerative
  • 1.5.6 Respiratory
  • 1.5.7 Genetic
  • 1.5.8 Infectious Diseases
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Antisense & RNAi Therapeutics Market Perspective (2015-2026)
• 2.2 Global Antisense & RNAi Therapeutics Growth Trends by Regions
  • 2.2.1 Antisense & RNAi Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Antisense & RNAi Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Antisense & RNAi Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Antisense & RNAi Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Antisense & RNAi Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Antisense & RNAi Therapeutics Players by Market Size
  • 3.1.1 Global Top Antisense & RNAi Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Antisense & RNAi Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Antisense & RNAi Therapeutics Market Concentration Ratio
  • 3.2.1 Global Antisense & RNAi Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Antisense & RNAi Therapeutics Revenue in 2019
• 3.3 Antisense & RNAi Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Antisense & RNAi Therapeutics Product Solution and Service
• 3.5 Date of Enter into Antisense & RNAi Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Antisense & RNAi Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Antisense & RNAi Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Antisense & RNAi Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Antisense & RNAi Therapeutics Market Size (2015-2020)
• 6.2 Antisense & RNAi Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Antisense & RNAi Therapeutics Market Size (2015-2020)
• 7.2 Antisense & RNAi Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Antisense & RNAi Therapeutics Market Size (2015-2020)
• 8.2 Antisense & RNAi Therapeutics Key Players in China (2019-2020)
• 8.3 China Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 8.4 China Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Antisense & RNAi Therapeutics Market Size (2015-2020)
• 9.2 Antisense & RNAi Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Antisense & RNAi Therapeutics Market Size (2015-2020)
• 10.2 Antisense & RNAi Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Antisense & RNAi Therapeutics Market Size (2015-2020)
• 11.2 Antisense & RNAi Therapeutics Key Players in India (2019-2020)
• 11.3 India Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 11.4 India Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Antisense & RNAi Therapeutics Market Size (2015-2020)
• 12.2 Antisense & RNAi Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Antisense & RNAi Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Antisense & RNAi Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Glaxo Smith Kline
  • 13.1.1 Glaxo Smith Kline Company Details
  • 13.1.2 Glaxo Smith Kline Business Overview
  • 13.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Introduction
  • 13.1.4 Glaxo Smith Kline Revenue in Antisense & RNAi Therapeutics Business (2015-2020))
  • 13.1.5 Glaxo Smith Kline Recent Development
• 13.2 Sanofi Aventis / Genzyme
  • 13.2.1 Sanofi Aventis / Genzyme Company Details
  • 13.2.2 Sanofi Aventis / Genzyme Business Overview
  • 13.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Introduction
  • 13.2.4 Sanofi Aventis / Genzyme Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.2.5 Sanofi Aventis / Genzyme Recent Development
• 13.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
  • 13.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Details
  • 13.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Business Overview
  • 13.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Development
• 13.4 Arbutus Biopharma Ltd.
  • 13.4.1 Arbutus Biopharma Ltd. Company Details
  • 13.4.2 Arbutus Biopharma Ltd. Business Overview
  • 13.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Introduction
  • 13.4.4 Arbutus Biopharma Ltd. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.4.5 Arbutus Biopharma Ltd. Recent Development
• 13.5 Silence Therapeutics
  • 13.5.1 Silence Therapeutics Company Details
  • 13.5.2 Silence Therapeutics Business Overview
  • 13.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Introduction
  • 13.5.4 Silence Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.5.5 Silence Therapeutics Recent Development
• 13.6 Bio-Path Holdings Inc.
  • 13.6.1 Bio-Path Holdings Inc. Company Details
  • 13.6.2 Bio-Path Holdings Inc. Business Overview
  • 13.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Introduction
  • 13.6.4 Bio-Path Holdings Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.6.5 Bio-Path Holdings Inc. Recent Development
• 13.7 Calando Pharmaceuticals
  • 13.7.1 Calando Pharmaceuticals Company Details
  • 13.7.2 Calando Pharmaceuticals Business Overview
  • 13.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.7.4 Calando Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.7.5 Calando Pharmaceuticals Recent Development
• 13.8 ICo Therapeutics
  • 13.8.1 ICo Therapeutics Company Details
  • 13.8.2 ICo Therapeutics Business Overview
  • 13.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Introduction
  • 13.8.4 ICo Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.8.5 ICo Therapeutics Recent Development
• 13.9 Quark Pharmaceuticals
  • 13.9.1 Quark Pharmaceuticals Company Details
  • 13.9.2 Quark Pharmaceuticals Business Overview
  • 13.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.9.4 Quark Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.9.5 Quark Pharmaceuticals Recent Development
• 13.10 Rexhan Pharmaceuticals
  • 13.10.1 Rexhan Pharmaceuticals Company Details
  • 13.10.2 Rexhan Pharmaceuticals Business Overview
  • 13.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 13.10.4 Rexhan Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 13.10.5 Rexhan Pharmaceuticals Recent Development
• 13.11 Biomarin/Prosensa
  • 10.11.1 Biomarin/Prosensa Company Details
  • 10.11.2 Biomarin/Prosensa Business Overview
  • 10.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Introduction
  • 10.11.4 Biomarin/Prosensa Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.11.5 Biomarin/Prosensa Recent Development
• 13.12 Regulus Therapeutics
  • 10.12.1 Regulus Therapeutics Company Details
  • 10.12.2 Regulus Therapeutics Business Overview
  • 10.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Introduction
  • 10.12.4 Regulus Therapeutics Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.12.5 Regulus Therapeutics Recent Development
• 13.13 Rxi Pharmaceuticals
  • 10.13.1 Rxi Pharmaceuticals Company Details
  • 10.13.2 Rxi Pharmaceuticals Business Overview
  • 10.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 10.13.4 Rxi Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.13.5 Rxi Pharmaceuticals Recent Development
• 13.14 Silenseed
  • 10.14.1 Silenseed Company Details
  • 10.14.2 Silenseed Business Overview
  • 10.14.3 Silenseed Antisense & RNAi Therapeutics Introduction
  • 10.14.4 Silenseed Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.14.5 Silenseed Recent Development
• 13.15 Dicerna Pharmaceuticals
  • 10.15.1 Dicerna Pharmaceuticals Company Details
  • 10.15.2 Dicerna Pharmaceuticals Business Overview
  • 10.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Introduction
  • 10.15.4 Dicerna Pharmaceuticals Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.15.5 Dicerna Pharmaceuticals Recent Development
• 13.16 Sirnaomics Inc.
  • 10.16.1 Sirnaomics Inc. Company Details
  • 10.16.2 Sirnaomics Inc. Business Overview
  • 10.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Introduction
  • 10.16.4 Sirnaomics Inc. Revenue in Antisense & RNAi Therapeutics Business (2015-2020)
  • 10.16.5 Sirnaomics Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer